In Vitro Study of the Effect of Gadolinium Contrast on Fibrocytes
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | July 2015 |
| End Date: | December 2017 |
| Contact: | Sundararaman Swaminathan, MD |
| Email: | ss4sa@virginia.edu |
| Phone: | 434-982-3577 |
Gadolinium contrast agents are frequently administered for MRI imaging. Very little is known
of its toxicity outside of patients with reduced renal function.
of its toxicity outside of patients with reduced renal function.
Gadolinium contrast is administered to patients during MRI imaging. Recently, the
investigators have observed potential gadolinium toxicity in some patients. To investigate
this, the investigators propose to collect clinical data and lab data obtained as a part of
clinical care. The investigators also plan to obtain 25 cc of peripheral blood at 2-4 weeks,
4-6 weeks and again at 3 months to identify unique monocyte signatures, gene polymorphisms,
and to quantitate circulating fibrocytes (in fresh blood and after culture). Plan to enroll
15 patients with kidney, pancreas or liver transplant and exposed to gadolinium contrast
agents, 15 non-transplant patients exposed to gadolinium contrast and 30 age- and
sex-matched healthy controls not exposed to gadolinium contrast.
investigators have observed potential gadolinium toxicity in some patients. To investigate
this, the investigators propose to collect clinical data and lab data obtained as a part of
clinical care. The investigators also plan to obtain 25 cc of peripheral blood at 2-4 weeks,
4-6 weeks and again at 3 months to identify unique monocyte signatures, gene polymorphisms,
and to quantitate circulating fibrocytes (in fresh blood and after culture). Plan to enroll
15 patients with kidney, pancreas or liver transplant and exposed to gadolinium contrast
agents, 15 non-transplant patients exposed to gadolinium contrast and 30 age- and
sex-matched healthy controls not exposed to gadolinium contrast.
Inclusion Criteria:
- Renal, pancreas or liver transplant OR those without organ transplant OR controls
- Age 18-70
- Both gender
- Exposure to gadolinium contrast agents (no exposure in controls)
- Have had a transplant, have had a contrast dye with an MRI
- Have not had a transplant and have had a contrast dye with an MRI
- Healthy person who has not had an MRI or gadolinium for any other reason.
Exclusion Criteria:
- End stage kidney disease or Stage 5
- Previous diagnosis of Nephrogenic Systemic Fibrosis
We found this trial at
1
site
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
Click here to add this to my saved trials
